drugset
drugset / Trial / NCT03455075

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

NCT03455075 ↗

Phase 2 Completed 92 enrolled Premier Research Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collabLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · collabUniversity of Washington · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

This is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to evaluate the spermatogenesis suppression after oral administration of Dimethandrolone Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.

Timeline

Start
2018-04-16
Primary completion
2020-03-05
Completion
2020-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dimethandrolone Undecanoate Unknown 100 mg Oral
Subject Dimethandrolone Undecanoate Unknown 200 mg Oral
Subject Dimethandrolone Undecanoate Unknown 400 mg Oral
Subject Levonorgestrel Small molecule 30 ug Oral

Indications

No indication recorded.